Celcuity, Inc. (NASDAQ:CELC) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Celcuity, Inc. (NASDAQ:CELC – Get Free Report) has been given an average rating of “Moderate Buy” by the sixteen analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $151.79.

CELC has been the subject of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a research report on Tuesday, September 1st. Stifel Nicolaus lowered their price objective on Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Citigroup reissued a “market outperform” rating on shares of Celcuity in a report on Monday, November 9th. Wall Street Zen raised Celcuity from a “strong sell” rating to a “sell” rating in a report on Saturday, November 14th. Finally, Citizens Jmp restated a “market outperform” rating and set a $177.00 target price on shares of Celcuity in a research report on Monday, August 17th.

Get Our Latest Stock Analysis on CELC

Institutional Investors Weigh In On Celcuity

A number of institutional investors and hedge funds have recently modified their holdings of CELC. PNC Financial Services Group Inc. grew its holdings in Celcuity by 20.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock worth $59,000 after acquiring an additional 86 shares during the period. EverSource Wealth Advisors LLC lifted its stake in shares of Celcuity by 15.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 944 shares of the company’s stock valued at $99,000 after purchasing an additional 124 shares during the period. Integrity Alliance LLC. lifted its stake in shares of Celcuity by 2.2% in the 3rd quarter. Integrity Alliance LLC. now owns 11,868 shares of the company’s stock valued at $944,000 after purchasing an additional 250 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Celcuity by 1.0% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 31,092 shares of the company’s stock valued at $3,253,000 after purchasing an additional 297 shares during the period. Finally, IFP Advisors Inc boosted its position in shares of Celcuity by 42.6% in the 3rd quarter. IFP Advisors Inc now owns 995 shares of the company’s stock worth $79,000 after purchasing an additional 297 shares during the last quarter. 63.33% of the stock is owned by institutional investors.

Celcuity Price Performance

CELC opened at $53.36 on Friday. Celcuity has a one year low of $53.20 and a one year high of $151.02. The company has a debt-to-equity ratio of 6.04, a current ratio of 14.62 and a quick ratio of 14.59. The company’s 50 day simple moving average is $69.19 and its 200-day simple moving average is $96.86. The stock has a market capitalization of $2.62 billion, a P/E ratio of -11.33 and a beta of 0.16.

Celcuity (NASDAQ:CELC – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($1.21) earnings per share for the quarter, topping the consensus estimate of ($1.51) by $0.30. Sell-side analysts anticipate that Celcuity will post -5.08 earnings per share for the current fiscal year.

Celcuity Company Profile

(Get Free Report)

Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways. Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.

Further Reading

Analyst Recommendations for Celcuity (NASDAQ:CELC)

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.